PT32 Cost-Effectiveness of Lorlatinib in Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer in China
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1029
https://www.valueinhealthjournal.com/article/S1098-3015(23)04159-1/fulltext
Title :
PT32 Cost-Effectiveness of Lorlatinib in Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04159-1&doi=10.1016/j.jval.2023.09.1029
First page :
Section Title :
Open access? :
No
Section Order :
10526